| Income Statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|---|
| Research and development | 50,221 | 54,515 | 36,957* | 60,635 |
| General and administrative | 11,439 | 15,509 | 9,370* | 10,799 |
| Total operating expenses | 61,660 | 70,024 | 46,326 | 71,434 |
| Operating loss | -61,660 | -70,024 | -46,326* | -71,434 |
| Interest expense | 2,632 | 2,269 | -604* | 3,198 |
| Other income, net | 2,577 | 3,208 | 6,124* | 4,053 |
| Loss before income tax | -61,715 | -69,085 | -39,598* | -70,579 |
| Income tax expense | 90 | 622 | 296* | 115 |
| Net loss | -61,805 | -69,707 | -39,894 | -70,694 |
| Of which net loss attributable to controlling interests shareholders | -61,805 | -69,707 | -39,894 | -69,729 |
| Basic EPS | -0.84 | -0.98 | -0.598 | -1.1 |
| Diluted EPS | -0.84 | -0.98 | -0.598 | -1.1 |
| Basic Average Shares | 73,915,296 | 71,273,650 | 66,738,955 | 63,369,984 |
| Diluted Average Shares | 73,915,296 | 71,273,650 | 66,738,955 | 63,369,984 |
MoonLake Immunotherapeutics (MLTX)
MoonLake Immunotherapeutics (MLTX)